ArticleClinical rheumatology2026
Incidence and prevalence of connective tissue disease (CTD)-associated interstitial lung disease in the United States.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesInterstitial lung disease (ILD) is a pulmonary manifestation of connective tissue diseases (CTDs). Limited data exist describing the epidemiology of CTD-ILD; therefore, this study aimed to estimate the incidence and prevalence of CTD-ILD in the US, overall and by CTD-ILD subtypes.
methodsPatients with CTD-ILD and rheumatoid arthritis (RA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), mixed CTD (MCTD), and Sjögren's disease (SjD) were identified from Optum
resultsILD was present in 4.3% (n = 21,366/496,690; Optum
conclusionConsistent age- and sex-adjusted CTD-ILD incidence and prevalence estimates between two large, demographically distinct US databases provide contemporary population-level estimates of CTD-ILD frequency and distribution that can inform disease screening and patient care. Key points • US CTD-ILD incidence estimated at 7.6 and 10.0/100,000 person-years and prevalence estimated at 46.7 and 43.4/100,000 persons. • Incidence and prevalence rates were highest in female patients, patients aged ≥ 65 years, and patients of Black African ancestry. • Incidence and prevalence rates varied between CTD subtypes and were highest for RA-ILD and lowest for MCTD-ILD.
Indexed as
Identifiers
42909770What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.